Presentation	Number (%)
Hoarseness	23 (47.92%)
Dysphagia	8 (16.67%)
Nasal obstruction	6 (12.50%)
Neck mass	5 (10.42%)
Dyspnea	1 (2.08%)
Epistaxis	1 (2.08%)
Facial swelling	1 (2.08%)
Lt. Facial pain\dysphagia	1 (2.08%)
Rt. check mass	1 (2.08%)
Stomatitis	1 (2.08%)

Presentation of studied population Table (1) :

Characteristic of the tumors in studied populations Table (2) ;

Variable	Summary statistics
Site Larynx Nasopharynx Hypopharynx Oral cavity Tongue Oropharynx Cheek	26 (54.17%) 9 (18.75%) 5 (10.42%) 3 (6.25%) 3 (6.25%) 1 (2.08%) 1 (2.08%)
Pathology SCC Undifferentiated Carcinoma NK SCC Anaplastic	15 (31.25%) 33 (68.75%) 2 (4.17%) 1 (2.08%)
Grade G1 G2 G2-3 G3 HG	4 (8.33%) 27 (56.25%) 4 (8.33%) 11 (22.92%) 2 (4.17%)
Stage III IVA IVB	20 (41.67%) 27 (56.25%) 1 (2.08%)
T classification T1 T2 T3 T4	2 (4.17%) 9 (18.75%) 23 (47.92%) 14 (29.17%)
N classification N0 N1 N2 N3	8 (16.67%) 14 (29.17%) 25 (52.08%) 1 (2.08%)

Variable	Summary statistics
Initial response Complete response Partial response Progressive disease Stationary disease Died Missed	34 (70.83%) 8 (16.67%) 1 (2.08%) 1 (2.08%) 1 (2.08%) 3 (6.25%)
Time to initial response Mean ± SD Median (range)	2.97±1.05 3.00 (2.00-6.00)
Duration to achieved response Mean ± SD Median (range)	16.33±13.53 12.00 (1.00-45.00)
Further outcome Complete response Partial response Progressive disease	30 (68.18%) 1 (2.77%) 13 (29.55%)
Site of progression if present Local Lung Both	9 (69.23%) 3 (23.08%) 1 (7.69%)
Over all response Progressive Responsive	12 (27.27%) 32 (72.73%)

Characteristics related to response Table (3)

Comparison between patients using / not using induction chemotherapy according to patients' characteristics Table (4) :

Variables	Induction chemo	P value		
v arrables	No	Yes	P value	
Age Mean± SD Median (range)	58.29±13.84 60.5 (18-77)	54.7±16.92 60 (20-70)	0.42	
Gender Females Males	5 (17.86%) 23 (82.14%)	10 (50.00%) 10 (50.00%)	0.02	
Smoking Non-smoker Smoker	9 (32.14%) 19 (67.86%)	10 (50.00%) 10 (50.00%)	0.21	

Factors	No.	Cum survival at 24 ms %	Cum survival at 36 ms %	Cum survival at end of study (max 45 ms) %	P-value
Whole group	34	73.79	67.08	67.08	
Age ≤60 >60	17 17	93.33 52.73	93.33 42.19	93.33 42.19	0.03
Gender Females Males	7 27	75.00 72.64	75.00 65.37	75.00 65.37	0.58
Smoking Non-smoker Smoker				65.63 64.12	0.43
Pathology SCC Others	26 8	66.86 87.50	59.43 87.50	59.43 87.50	0.39
Grade G1/G2 More than G2	22 12	65.63 82.50	56.25 82.50	56.25 82.50	0.57
Stage III IVA/IVB	16 18	80.81 67.46	80.81 53.97	80.81 53.97	0.15
T classificatio n T1/T2 T3/T4	10 24	83.33 69.01	83.33 57.51	83.33 57.51	0.29
N classificatio n N0/ N1 N2/N3	17 17	70.75 75.29	53.06 75.29	53.06 75.29	0.61
Induction chemothera py Yes No	13	70.00 74.51	70.00 65.20	70.00 65.20	0.69

Disease free survival its relation to different factorsTable(5) ;

Factors	No.	Cum survival	Cum survival	Cum survival	P-
		at 24 ms %	at 36 ms %	at end of study (max 62ms) %	value
Whole	48	62.52	59.39	59.39	
group					
Age ≤60	25	59.95	59.95	59.95	0.91
>60	23	64.67	58.21	58.21	
Gender					
Females	15	41.90	41.90	41.90	0.03
Males	33	71.73	67.24	67.24	
Smoking Non-smoker	19	55.83	55.83	55.83	0.34
Non-smoker	29	66.42	60.89	60.89	0.54
Smoker					
Pathology					
SCC	38	60.22	56.20	56.20	0.76
Others	10	70.00	70.00	70.00	
Grade G1/G2	31	62.44	57.24	57.24	0.92
More than	17	61.94	61.94	61.94	0.72
G2					
Stage					
	20 28	62.33 63.31	62.33	62.33	0.68
IVA/IVB T	28	03.31	56.98	56.98	
ı classificatio	11	90.00	90.00	90.00	0.03
n	37	54.00	50.16	50.16	0.02
T1/T2					
T3/T4					
N	22	52 70	52 70	52 70	0.56
classificatio n	22	53.79 70.36	53.79 64.50	53.79 64.50	0.56
N0/ N1					
N2/N3					
Induction					
chemothera	20	58.85	58.85	58.85	0.84
py Yes	20 28	58.85 64.71	60.39	58.85 60.39	0.04
No	_				

Overall survival its relation to different factorsTable (6)

X 7	Induction chemo				
Variables	No Yes		P value		
Acute toxicity					
Mucositis grade 0 1 2 3 4	1 (3.57%) 11 (39.29%) 5 (17.86%) 10 (35.71%) 1 (3.57%)	0 6 (30.00%) 6 (30.00%) 4 (20.00%) 4 (20.00%)	0.22		
Acute skin toxicity grade 0 1 2 3 4	2 (7.14%) 9 (32.14%) 11 (39.29%) 5 (17.86%) 1 (3.57%)	0 10 (50.00%) 3 (15.00%) 4 (20.00%) 3 (15.00%)	0.16		
Dysphagia No Yes	7 (25.00%) 21 (75.00%)	5 (25.00%) 15 (75.00%)	1.00		
Chronic toxicity					
No chronic toxicity Pigmentation Skin Xerostomia	18 (64.29%) 1 (3.57%) 6 (21.43%) 3 (10.71%)	17 (85.00%) 0 0 3 (15.00%)	0.12		

Comparison between patients using / not using induction chemotherapy according to toxicity Table (7) :